The Full Wiki

More info on Dimebolin

Dimebolin: Map


Wikipedia article:

Map showing all locations mentioned on Wikipedia article:

Dimebolin hydrochloride (brand name Dimebon) is an antihistamine drug which has been used clinically in Russiamarker since 1983.

Research is continuing in both Russia and western nations into potential applications as a neuroprotective drug to combat Alzheimer's Disease and, possibly, as a nootropic as well.


It is an orally active small molecule that has been shown to inhibit brain cell death in preclinical studies of Alzheimer's disease and Huntington's disease, making it a potential treatment for these and other neurodegenerative diseases. Research suggests that it may also have cognition-enhancing effects in healthy individuals, in the absence of neurodegenerative disease pathology.

Alzheimer's disease

Recently dimebolin has attracted renewed interest after being shown to have positive effects on persons suffering from Alzheimer’s disease. Animal studies showing potential beneficial effects on Alzheimer's disease models were shown in Russian research in 2000. Preliminary results from human trials have also been promising. In an initial six-month phase II trial, results have shown that at 12 months there was significant improvement over placebo. Dimebolin showed promising results in a Phase III-equivalent double blind trial in Russia with mild–moderate stage patients.Apr 2009 Pfizer and Medivation initiate a phase III trial (CONCERT study) aiming for FDA approval.

On July 2009 Pfizer and Medivation announced that latrepirdine will be the proposed international nonproprietary name for Dimebon for the treatment of Alzheimer's.


Dimebolin appears to operate through multiple mechanisms of action, both blocking the action of neurotoxic beta-amyloid proteins and inhibiting L-type calcium channels, modulating the action of AMPA and NMDA glutamate receptors, and may exert a neuroprotective effect by blocking a novel target that involves mitochondrial pores, which are believed to play a role in the cell death that is associated with neurodegenerative diseases and the aging process. It also blocks a number of other receptors including alpha-Adrenergic receptors and the serotonin receptor subtypes 5-HT2C, 5-HT5A and 5-HT6.


  1. "Pfizer and Medivation Initiate Phase 3 Trial of Dimebon Added to Donepezil in Patients with Alzheimer's Disease"
  2. Wu J, Li Q, Bezprozvanny I. Evaluation of Dimebon in cellular model of Huntington's disease. Molecular Neurodegeneration. 2008 Oct 21;3-15. PMID 18939977

See also

Embed code:

Got something to say? Make a comment.
Your name
Your email address